Showing 4701-4710 of 6036 results for "".
- EssilorLuxottica and CooperCompanies Finalize Joint Venturehttps://modernod.com/news/essilorluxottica-and-coopercompanies-finalize-joint-venture/2480705/EssilorLuxottica and CooperCompanies have announced the finalization of their joint venture agreement for SightGlass Vision. This collaboration accelerates the commercialization of novel spectacle lens technologies to expand the myopia management category. SightGlass Vision’s Diffusion
- Bryan Wolynski Named Chief Technology Officer at Lighthouse Guildhttps://modernod.com/news/bryan-wolynski-named-chief-technology-officer-at-lighthouse-guild/2480702/Bryan Wolynski, OD, FAAO, has been named Chief Technology Officer at Lighthouse Guild. Dr. Wolynski will oversee all technology resources for the organization, including the recently opened Lighthouse Guild Technology Center, and will develop strategies to bring the latest technological advances
- Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidatehttps://modernod.com/news/orasis-pharmaceuticals-concludes-phase-3-clinical-trials-for-presbyopia-candidate/2480699/Orasis Pharmaceuticals announced the completion of its NEAR-1 and NEAR-2 phase 3 clinical studies. “Orasis is committed to reshaping vision possibilities by developing a presbyopia eye drop with the patient in mind,” said Elad Kedar, Chief Executive Officer of Orasis. &ldquo
- RG6501 (OpRegen) Full Phase 1/2a Results to Be Presented at ARVO Annual Meetinghttps://modernod.com/news/rg6501-opregen-full-phase-12a-results-to-be-presented-at-arvo-annual-meeting/2480697/Lineage Cell Therapeutics announced that full results from a phase 1/2a clinical study of RG6501 (OpRegen), a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2022 Associ
- Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink Therapyhttps://modernod.com/news/glaukos-announces-commencement-of-phase-2-corneal-health-clinical-program-for-third-generation-ilink-therapy/2480696/Glaukos announced that it has commenced a phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Glaukos’ iLink pharmaceutical platform consists of novel single-use drug formulations that are bio-activa
- SECO International and National Academy of Opticianry Expand Partnership to Bring Optician-Focused Education to SECO 2023https://modernod.com/news/seco-international-and-national-academy-of-opticianry-expand-partnership-to-bring-optician-focused-education-to-seco-2023/2480695/SECO International announced that it has expanded a partnership with the National Academy of Opticianry (NAO) to bring a dedicated educational track for opticians to SECO 2023. The NAO, founded in 1963, represents opticians worldwide and is dedicated solely to education and training of all o
- Bunkers That Save Sight? UConn Researchers Take a Close Lookhttps://modernod.com/news/bunkers-that-save-sight-uconn-researchers-take-a-close-look/2480693/Chronically stressing the retina can weaken it and damage our ability to see. But retinal cells have a remarkable ability to wall off damage, a team of neuroscientists led by UConn Health reports in the 1 March issue of PNAS. The w
- SECO Announces Its 2022 Award Winnershttps://modernod.com/news/seco-announces-its-2022-award-winners/2480691/SECO International announced the recipients of its 2022 awards. The awards recognize leaders in optometry and their significant contributions to the profession. “It is an honor and privilege to recognize this outstanding group of leaders and their contribution to the pr
- NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trialhttps://modernod.com/news/novasight-announces-successful-results-of-pivotal-amblyopia-treatment-trial/2480689/NovaSight announced positive pivotal data from its multicenter, randomized, controlled trial of CureSight, an eye-tracking based, digital treatment device for amblyopia (lazy eye). The study, which randomized 103 participants aged 4 to 9, compared the improvement in visual outcomes achieved
- Théa Completes its Acquisition of Akorn’s Branded Ophthalmic Productshttps://modernod.com/news/thea-completes-its-acquisition-of-akorns-branded-ophthalmic-products/2480688/Théa Pharma announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn. The transaction expands Théa’s eye care portfolio in the United States. Financial terms of the deal were not disclosed. &